TDIV — the First Trust NASDAQ Technology Dividend Index Fund — enters the last week of August with one signal cutting clearly against the grain of an otherwise calm picture: options traders are hedging at a rate well above normal.
The put/call ratio jumped to 0.21 this week, nearly 2.5 standard deviations above its 20-day average of 0.11. For context, TDIV's PCR has hugged the low end of its 52-week range for most of the summer, rarely breaching 0.10. The recent spike to 0.23 on August 24, followed by a still-elevated 0.21, marks the most defensive options posture this fund has seen in months — without an obvious catalyst from the underlying tech-dividend universe to explain it. That divergence is the week's most interesting tension.
Short interest tells a different, far quieter story. Bearish positioning in the fund is negligible — roughly 0.41% of free float — and the borrow market has eased noticeably. Availability climbed to 208%, meaning more than twice as many shares are available to borrow as are currently lent out. That's a dramatic reversal from the tight lending conditions seen in early August, when availability dropped to around 51% on August 13 and 50% on August 11. Cost to borrow ticked up slightly on the week to 3.69%, but remains well below the 4.1%-4.2% range that prevailed through late July and early August. ORTEX's short score for the fund has also drifted lower, to 44.0 from 49.1 two weeks ago — a direction that reflects easing short-side pressure rather than building conviction. Positioning looks loose rather than charged.
The broader fund picture is constructive on price but measured on income. TDIV added 6.5% over the past month, reaching $114.22, even as it slipped marginally on the week. The most recent dividend, paid in late June, came in at $0.42 per share — up from $0.32 in March — a step-up that reflects the stronger earnings cycle across the fund's underlying tech holdings. Institutional ownership is spread across wealth-management platforms: LPL Financial holds the largest stake at roughly 9.6% of shares, followed by Morgan Stanley at 6.6%. Notably, Morgan Stanley added nearly 60,000 shares in Q2, and Raymond James added 56,000 — a steady drift of platform capital into the fund rather than any single concentrated bet.
What's worth watching next is whether the PCR spike turns out to be a one-week anomaly — perhaps tied to broader index hedging activity — or marks the beginning of a sustained shift in how options traders are positioning around tech-dividend names heading into the autumn volatility window.
See the live data behind this article on ORTEX.
Open TDIV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
